Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 20/20 | 0.63 |
| ▸ | LGALS1 | P09382 | 7/20 | 0.62 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.62 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30170947 | 0.91 | LGALS3 (0.61) | LGALS3LGALS1LGALS8LGALS9 | |
| SCHEMBL22542393 | 0.89 | LGALS3 (0.72) | LGALS3LGALS1LGALS8 | |
| SCHEMBL30170990 | 0.84 | LGALS3 (0.59) | LGALS3LGALS1LGALS8 | |
| SCHEMBL25226825 | 0.84 | LGALS3 (0.59) | LGALS3LGALS1LGALS8 | |
| SCHEMBL30171086 | 0.84 | LGALS3 (0.59) | LGALS3LGALS1LGALS8 | |
| SCHEMBL30170914 | 0.84 | LGALS3 (0.57) | LGALS3LGALS1LGALS8LGALS9 | |
| SCHEMBL25613277 | 0.84 | LGALS3 (0.57) | LGALS3LGALS1LGALS8 | |
| SCHEMBL25228388 | 0.84 | LGALS3 (0.57) | LGALS3LGALS1LGALS8LGALS9 | |
| SCHEMBL30242097 | 0.84 | LGALS3 (0.57) | LGALS3LGALS1LGALS8LGALS9 | |
| SCHEMBL24420887 | 0.84 | LGALS3 (0.53) | LGALS3LGALS1LGALS8LGALS9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212158-A1 | SMALL MOLECULE INHIBITORS OF GALECTIN-3 | BRISTOL MYERS SQUIBB CO (US) | 2023-07-06 | — | — | US | disclosed |
| US-20230212158-A1 | SMALL MOLECULE INHIBITORS OF GALECTIN-3 | BRISTOL MYERS SQUIBB CO (US) | 2023-07-06 | — | — | US | disclosed |
| EP-4149939-A1 | SMALL MOLECULE INHIBITORS OF GALECTIN-3 | Bristol-Myers Squibb Company (US) | 2023-03-22 | — | — | EP | disclosed |
| CN-115551850-A | Small molecule inhibitors of galectin-3 | 百时美施贵宝公司 | 2022-12-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212158-A1 | SMALL MOLECULE INHIBITORS OF GALECTIN-3 | LGALS3, LGALS1, LGALS3BP | LGALS3 1/4885LGALS1 2/4885LGALS8 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.